Navigation Links
Independent publication supports the profile of CeNeS phase II,compound, CNS 5161

CAMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, notes the publication of an independent study in the respected scientific journal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeS is developing CNS 5161 as a potential treatment for neuropathic pain. The independent study builds on the work that CeNeS has already undertaken with CNS 5161.

In the study reported in 'Synapse', Dr Anat Biegon and her group at the Brookhaven National Laboratory, New York, USA, have studied a radioactively labelled version of CNS 5161. They have shown that CNS 5161 is a selective and high affinity NMDA receptor antagonist with preferential binding to the activated form of the receptor. The group also demonstrated that CNS 5161 penetrates the brain well and can be used to label selectively brain NMDA receptors in vivo. Dr Biegon proposes that a radioactive form of CNS 5161 may be used as an agent to monitor NMDA receptors in the human brain using Positron Emission Tomography ("PET") and notes that "the significance of a selective, validated radiopharmaceutical agent suitable for detecting widespread as well as highly localized changes in the NMDA receptor in the living brain cannot be exaggerated".

Data from Phase I and Phase IIa studies previously carried out by CeNeS have shown that CNS 5161 has analgesic properties in patients with neuropathic pain, but does not induce the severe psychotomimetic side-effects associated with other NMDA antagonists.

Neil Clark, Chief Executive of CeNeS, said:

"The data published in this paper supports and extends our original findings with CNS 5161. It has proved very difficult to develop a PET agent with the properties that make it possible to monitor NMDA receptor activation in the human brain. The profile of CNS 5161 as a selective, high affinity and brain-penetrating agent now make this a
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
8. CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
11. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
Post Your Comments:
(Date:7/2/2015)... , and DURHAM, N.C. , July ... today announced its acquisition of assets related to the ... PFE ) that had previously been obtained as part ... also acquired all of Pfizer,s rights to the "Icagen" ... brand and will provide comprehensive services for ion channel ...
(Date:7/2/2015)... TOKYO , July 2, 2015  Konica Minolta, ... today announced that it has acquired Sawae Technologica Ltda., ... Brazil , through its Brazilian healthcare ... . Local Brazil ... increasing population exceeding 200 million, significant healthcare ...
(Date:7/2/2015)... 2, 2015  The Commission for Certification in ... an organization that represents pharmacists in acute and ... continuing education for recertification of Certified Geriatric Pharmacists.  ... programs for this purpose.  ASHP will join the ... for the CCGP Professional Development Program. ...
Breaking Medicine Technology:Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3Commission for Certification in Geriatric Pharmacy Adds ASHP as Professional Development Program Provider 2
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that ... Food and Drug Administration for its Abbreviated New ... Powder for Solution. Perrigo is expecting to begin ... under store brand labels and is comparable to ...
... BATESVILLE, Ind., Oct. 6 Hill-Rom Holdings, Inc. (NYSE: ... has unanimously approved enhancements to the Company,s corporate ... of majority voting in uncontested elections. The ... for a majority voting standard for the election of directors ...
Cached Medicine Technology:Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 2Hill-Rom Announces Corporate Governance Enhancements 2Hill-Rom Announces Corporate Governance Enhancements 3Hill-Rom Announces Corporate Governance Enhancements 4
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the only ... lead a national president recruitment for Regional Care, Inc. in Scottsbluff, ... E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Erie County ... 2015 at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. of William ... practical points of investigating these types of cases. , Each year, New York ...
(Date:7/3/2015)... ... 03, 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce ... Lawsuit Center website. Just as the previous version did, the new website will serve ... updates and ovarian cancer warning information. The site is routinely updated with news articles ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room , the largest ... MD as the new Medical Director of its Frisco facility. , “We are pleased ... facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:7/3/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... biblical truth and expose popular lies regarding proper relationships according to the bible. ... goes into the core of the subject by explaining why certain types of sexual ...
Breaking Medicine News(10 mins):Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... evidence of the H1N1 virus in animals in Africa. In one ... studied had been exposed to the H1N1 virus, commonly known as ... every pig in this village was exposed," said Thomas B. Smith, ... of the research. "Africa is ground zero for a new pandemic. ...
... , FRIDAY, Sept. 23 (HealthDay News) -- Fred Wyand has ... the public health response to human papillomavirus, or HPV. ... News , a bimonthly newsletter published by the American Social ... HPV is a sexually transmitted disease that most people ...
... -- There is a genetic link between schizophrenia and ... a new study indicates. Researchers identified 11 genetic ... which play a role in people,s risk for these ... into the causes of both conditions. "Schizophrenia and ...
... brain doesn,t stop developing at adolescence, but continues well into ... & Dentistry at the University of Alberta. It ... human brain stopped developing in adolescence. But now there is ... to medical research conducted in the Department of Biomedical Engineering ...
... CHICAGO --- A drug used to treat cancer may also ... organs or skin, such as pulmonary fibrosis or scleroderma. ... of fibrotic proteins in human cells and the development of ... to a new Northwestern Medicine study published in the journal ...
... , THURSDAY, Sept. 22 (HealthDay News) -- People with type ... an increased risk of developing pancreatitis and pancreatic cancer, a ... (exenatide) may raise the risk of thyroid cancer. Although ... noted. "We have raised concern that there may be ...
Cached Medicine News:Health News:UCLA scientists find H1N1 flu virus prevalent in animals in Africa 2Health News:UCLA scientists find H1N1 flu virus prevalent in animals in Africa 3Health News:Stress the 'Human' in HPV, One Man Suggests 2Health News:Stress the 'Human' in HPV, One Man Suggests 3Health News:Genetic Links Seen Between Bipolar Illness and Schizophrenia 2Health News:Some brain wiring continues to develop well into our 20s: U of A study 2Health News:Cancer drug may also work for scleroderma 2Health News:Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests 2Health News:Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests 3Health News:Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests 4
... Streck-Kleen is an enzymatic cleanser for ... Coulter® Counters. The 475ml bottle has a ... MD Series instruments that require manual addition ... is a feature of this product. The ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
... balanced electrolyte solution manufactured for use as ... sizing. Streck-Diluent III is for use on ... JS, JT, S-Plus IV, V, VI with ... 1400 and 1600. The shelf life is ...
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
Medicine Products: